The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa
|
|
- Edmund McGee
- 5 years ago
- Views:
Transcription
1 European Journal of Endocrinology (2002) ISSN CLINICAL STUDY The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa M T Muñoz 1, G Morandé 3, J A García-Centenera 4, F Hervás 4,JPozo 1 and J Argente 1,2 1 Division of Pediatric Endocrinology, 2 Laboratory of Research, Universidad Autónoma, Department of Pediatrics, Hospital Universitario Niño Jesús, 3 Division of Pediatric Psychiatry and 4 Division of Endocrinology, Hospital Santa Cristina, Madrid, Spain (Correspondence should be addressed to J Argente, Hospital Universitario Niño Jesús, Department of Endocrinology, Avda Menéndez Pelayo, 65, Madrid, Spain; argentefen@teleline.es) Abstract Objective: Profound osteopenia is a serious complication of anorexia nervosa (AN). The aim of this work was to study the effect of prolonged AN on lumbar spine bone mineral density (BMD) and to determine whether oral estrogen administration prevents bone loss in women with this disorder. Subjects and Methods: Thirty-eight amenorrheic women with AN (mean age: 17.3 years) were treated with estrogen (50 mg of ethinyl estradiol) and gestagen (0.5 mg of norgestrel) during 1 year. Clinical variations, biochemical indices and BMD were studied at three different time points, including after a period of amenorrhea of at least 12 months ðn ¼ 38Þ, after the administration of estrogens for 1 year ðn ¼ 22Þ, and after a 1-year follow-up period ðn ¼ 12Þ. Results: Initial mean BMD was significantly lower than normal (22:1^0:8 S.D.) and less than 22.5 S.D. below normal in 38% of the women with AN. The estrogen-treated group had no significant change in BMD even after the follow-up period and partial recovery of weight. Estradiol and total IGF-I levels were significantly lower throughout the study. All subjects had normal thyroxine (T 4 ) and TSH levels and calcium metabolism. However, total tri-iodothyronine (T 3 ) was decreased in all anorexic subjects in the first and second study points and were within normal limits after the follow-up period. Conclusions: (1) Estrogen replacement alone cannot prevent progressive osteopenia in young women with AN. (2) Other factors, such as the loss of weight, the duration of the amenorrhea and the low levels of total insulin-like growth factor-i (IGF-I) could contribute to the loss of bone mass in women with this disorder. European Journal of Endocrinology Introduction Prolonged amenorrhea is a complication present in the majority of patients with anorexia nervosa (AN) (1). Osteoporosis is another important medical complication commonly associated with AN. Adolescence is a particularly critical time for bone mineral accretion, as more than half of the bone calcium is normally laid down during the teenage years. Hence, AN may result in profound deficits in bone mass which may not be fully reversible. The pathogenesis of osteoporosis in AN has not been completely characterized. While low body mass and amenorrhea are clearly important variables, other factors, such as low calcium intake, increased levels of glucocorticoids and insulin-like growth factor-i (IGF-I) deficiency (2), may also be involved. There is some published data on trabecular bone mineral density (BMD) in adult women with AN (3, 4), but it is still unknown whether there is a progressive or permanent decline in bone mass. Although the role of estrogen replacement therapy in preventing bone loss in menopausal women has been clearly established, no studies have been carried out to determine whether it is beneficial in young women with premenopausal osteopenia. The aim of this study was to determine whether oral estrogens improve BMD in anorexic patients with osteopenia. Subjects and methods Study protocol We studied 38 amenorrheic women with AN, as defined by the DSM-IV criteria from the latest Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatry Association (5). The mean ages of the controls and patients with AN were 17:3^0:4 and 17:4^ 1:5 years respectively. Every patient consulted the q 2002 Society of the European Journal of Endocrinology Online version via
2 46 M T Muñoz and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) 146 Division of Endocrinology of our hospital after the diagnosis of AN was made at the Division of Psychiatry of the same hospital. All normal subjects were referred to the Division of Endocrinology for suspected endocrine abnormalities and were found to be normal with a height and weight between 21 and +1 S.D. according to Spanish standards (6). The study subjects were investigated at three different time points: T1 ¼ after a period of amenorrhea of at least 12 months ðn ¼ 38Þ, T2¼ after the administration of estrogens (50 mg of ethinyl estradiol) and gestagens (0.5 mg of norgestrel) during 1 year ðn ¼ 22Þ, and T3 ¼ after a follow-up period of 1 year ðn ¼ 12Þ. No patient had previously received treatment with estrogens. In all subjects amenorrhea occurred in close temporal association with the onset of anorexia. No patient had any other illness or was taking any medication known to affect bone mass, including thyroid hormones, anti-seizure medications or glucocorticoids. In addition, all of the patients had reached their target height when the diagnosis was made. All patients were scheduled for a complete history, including details regarding menstrual function, age of menarche, exercise, alcohol use, other medications and a physical examination. The body mass index (BMI) was calculated as weight (kg)/height (m) 2. The BMI score was based upon normative data from Spanish women (6). After the first visit, the patients received treatment with ethinyl estradiol (50 mg/day) and gestagens (0.5 mg norgestrel). Treatment compliance was evaluated every 3 months through clinical controls. All subjects were informed of the purpose of the study and gave consent as required by the local human ethics committee. Hormone assays A gonadotrophin-releasing hormone (GnRH) stimulation test was performed (100 mg i.v. Luforan) for the determination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Blood samples were obtained at 230, 0, 30, 60, 90 and 120 min after the administration of GnRH. Serum FSH and LH measurements were performed by immonoradiometric assay (IRMA; Sorin, Biomédica, Vercelli, Italy). Serum estradiol levels were measured by RIA (Diagnostic Products Corporation, Los Angeles, CA, USA). Total IGF-I levels were determined by RIA (Nichols Laboratories, San Juan Capistrano, CA, USA) after acid ethanol extraction of serum. Measurements of tri-iodothyronine (T 3 ), thyroxine (T 4 ) and thyrotrophin (TSH) were performed by using RIA. In these samples, serum levels of calcium, phosphate, tartrate-resistant acid phosphatase, parathyroid hormone (PTH) and osteocalcin were also measured. The calcium and phosphate were determined by an autoanalyzer Vitros 750 (Johnson & Johnson). Tartrate-resistant acid phosphatase measurements were performed by kinetic reaction inhibiting its activity by adding tartrate. The PTH and osteocalcin were performed by chemiluminescence (Imulite, DPC). Intraand interassay coefficients of variation were 2.75% and 3.5% for FSH, 2.75% and 3.17% for LH, 5.3% and 6.4% for estradiol, 4.9% and 8.9% for IGF-I, 4.8% and 6% for PTH, and 5.2% and 6.2% for osteocalcin. BMD BMD (g/cm 2 ) of the lumbar spine (L 2 L 4 ) was measured by Dual-Energy X Ray Absorptiometry with a Lunar DPX-L-densitometer model at the three different points of the study. Z-score data (measured result population mean/standard deviation) were calculated for all patients using normative data of a standard Spanish population of girls between 15 and 20 years old. The control group consisted of 14 women, Tanner V, of similar age, with regular menses and with no history of food disorders (7). Statistical analysis All data are reported as the mean^s:e:m: When only two experimental groups were compared, Student s test was applied. For more than two experimental groups, analysis was performed by a one-way ANOVA or ANOVA with repeated measures, followed by Scheffé s F test. Correlations were performed using simple regression analysis. P, 0:05 was chosen as the level of significance. Results Clinical and auxological data Of the 38 women who entered the study, 22 completed the treatment. The secondary amenorrhea had a mean duration of 2^1 years. At the beginning of the study, the relationship between weight/height, expressed in S.D. of the BMI for age and sex, was 21:4^0:5 (Table 1) and the interval between menarche and the onset of the amenorrhea was 2:6^0:8 years. Hormone studies Basal and GnRH-stimulated FSH and LH levels were within the normal limits when compared with the corresponding control group of the same age and sex at the beginning of the follicular phase (FSH basal ¼ 5.7^3 mui/ml; FSH peak ¼ 13^6mUI=ml; LH basal ¼ 4:7^4 mui=ml; LH peak ¼ 46^24 mui=ml). Estradiol levels were significantly lower at all three time points of the study: T1 ¼ 28^15 pg=ml; T2 (after treatmentþ ¼28^15 pg=ml; T3 ðfollow-upþ ¼ 25^18 pg=ml (Table 2). Serum IGF-I concentrations were significantly lower throughout the study (T1 ¼ 344^113 ng=ml; T2 ¼ 349^84 ng=ml; T3 ¼ 361^24 ng/ml) (Fig. 1). All subjects had normal total
3 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) 146 Effects of estrogen on BMD in anorexia nervosa 47 Table 1 BMI, calcium, phosphate, tartrate-resistant acid phosphatase (FaTr) and PTH serum levels. Values are means^s.e.m.s. BMI (S.D.)* Calcium (mg/dl) Phosphate (mg/dl) FaTr (IU) PTH Initial ðn ¼ 38Þ 21.4^ ^ ^ ^1.0 37^21 Final ðn ¼ 22Þ 20.9^ ^ ^ ^0.5 35^16 Follow-up ðn ¼ 12Þ 20.6^ ^ ^ ^0.5 35^10 * Values are the means of the S.D.s of the BMI of age and sex (^S.E.M.s). Figure 1 Schematic representation of mean^s.d. serum levels of total IGF-I in patients with AN. Initial, final and follow-up periods in estrogen-treated patients (***P, 0:01). T 4 and TSH levels (Table 2); however, total T 3 was decreased in all subjects during the first and second time periods of the study and were within normal limits after the follow-up period (T1 ¼ 0:8^0:2 ng=ml; T2 ¼ 0:9^0:1ng=ml; T3 ¼ 1^0:1ng=ml) (Fig. 2). Calcium, phosphate, tartrate-resistant acid phosphatase, PTH and osteocalcin levels were within the limits of normality at all three time points (Table 1). BMD At the beginning of the study, the lumbar spine BMD mean was 22:1^0:8 (range: to 20.5 S.D.). After a year of treatment with estrogens the BMD was 21:8^0:8 S.D. (range to 20.3 S.D.) in the 22 patients that completed this stage. There was no difference in these patients in their starting BMD and after 1 Figure 2 Schematic representation of mean^s.d. serum levels of total T 3 in patients with AN. Initial, final and follow-up periods in estrogen-treated patients. The horizontal bar represents the normal mean. year of treatment. After the follow-up period the mean BMD in the 12 patients that completed the study was 22:1^0:8 S.D. (range 23.5 to 20.4 S.D.; Fig. 3). There was no difference in the mean BMD of these 12 patients at any stage of the study. Of the 38 patients starting the study, 62% had a BMD between 21 S.D. and 22.5 S.D. and 38% had a BMD,22.5 S.D. No significant correlation was found between the BMD and the duration of the amenorrhea, BMI, estradiol levels, calcium phosphate metabolites or IGF-I levels. However, a significant correlation was found between the BMD and T 3 levels (r ¼ 0:59, P, 0:01). Discussion In this prospective study of 38 young women with AN, we demonstrated a profound reduction in BMD. Thirtyeight percent of the patients had a BMD greater than Table 2 Estradiol, T 3,T 4, TSH and IGF-I serum levels. Values are means^s.e.m.s. Estradiol (pg/ml) T 3 T 4 TSH (miu/ml) IGF-I Initial ðn ¼ 38Þ 24^8 0.8^ ^ ^ ^113 Final ðn ¼ 22Þ 28^15 0.9^ ^ ^ ^113 Follow-up ðn ¼ 12Þ 25^18 1.1^ ^ ^ ^66
4 48 M T Muñoz and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) 146 Figure 3 Schematic representation of BMD expressed in S.D. with respect to age and sex, in patients with AN. Initial, final and follow-up periods in estrogen-treated patients. 2.5 S.D. below normal, with 62% having a BMD between 21 and 22.5 S.D. for their age and sex according to the criteria of the World Health Organization (8). The estrogen-treated group had no significant change in BMD even after the follow-up period and partial weight recovery. This report confirms the progressive loss of trabecular bone in adult women with chronic AN and prolonged amenorrhea. We found that, in contrast to the beneficial effects of estrogen during menopause, young women with AN have persistent osteopenia despite estrogen replacement. No further deterioration of the BMD appeared to take place. Unfortunately, we cannot evaluate this statistically due to the lack of an adequate control group of patients with AN of similar characteristics. Reduced bone mass in young women with AN has been clearly shown in several cross-sectional studies; however, few prospective data are available regarding the natural process of bone loss (3, 4, 9, 10). The more precocious the amenorrhea, the more severe the osteopenia and if menarche was never achieved the osteopenia is even more severe. Furthermore, the longer the period of amenorrhea the more severe the osteopenia. The long-term outcome of osteopenia in these patients is not well known. Rigotti et al. (11), in a longitudinal study of 27 adult women with AN, found no improvement in the BMD after a period of 25 months, in spite of the fact that most of the patients gained weight and some even menstruated spontaneously. In 15 adolescents with AN followed during a period of months, Bachrach et al. (12) observed an increase in BMD in relationship to the weight increase. Nevertheless, at the end of the study, osteopenia persisted in approximately 50% of the patients. Although more studies are necessary to establish with clarity the factors involved in the evolution of osteopenia, the available data suggest that the recovery age could be one of the most important factors in predicting the long-term outcome of these patients (13). This hypothesis would be in agreement with the physiological aspects of bone mass acquisition that suggest that there is a critical period after which the possibility of recovering bone mass could be very reduced. The therapeutic potential of estrogens in treating osteopenia of patients with AN and extended amenorrhea is controversial (14). Most studies indicate that the spontaneous recovery of menstruation is accompanied by a significant improvement in BMD. On the contrary, and in agreement with our findings, estrogen therapy does not seem to induce a meaningful recovery of the BMD (3, 4, 15) and several possibilities could explain this failure. One possibility is that the estrogen dose which is effective in treating postmenopausal women is inadequate in a younger population. Second, whether continued improvement in bone mass may be seen in patients treated for a longer period of time than the current study is unknown. A third and more likely explanation is that estrogen therapy alone cannot correct the multiple factors contributing to bone loss in women with AN. In addition to profound hypoestrogenism, nutritional and other hormonal variables have been implicated in the pathogenesis of bone loss (16). These factors, including IGF-I deficiency, cortisol excess and decreased androgen production, are unaffected by estrogen administration and may have a continuing deleterious effect on bone mass (17). Nutritional factors are important in regulating the growth and mineralization of bone and provide the substances necessary for this process (18). Other systemic hormones, including growth hormone (GH), growth factors such as IGF-I, insulin, thyroid hormones, androgens, estrogens and glucocorticoids, are also implicated (19). One of the most important agents in the regulation of skeletal growth and mineralization is IGF-I. Circulating IGF-I exerts both autocrine and paracrine functions (20). Our patients had reduced IGF-I levels at all three time points of the study. The finding of low levels of IGF-I in patients with AN, as in other situations of malnutrition, has been widely described in the literature (21). However, the pathophysiological mechanisms that mediate this phenomenon are only partially known (22). Surprisingly, in spite of partial weight recovery a simultaneous recovery of IGF-I levels is not seen. It is possible that this recovery is insufficient in either time or extent to overcome the numerous mechanisms that are underway in these patients. Grinspoon et al. (23) subcutaneously administered recombinant IGF-I for 6 days to 23 women with AN who had a 54% decrease in BMD. This resulted in an increase of the markers of both bone production and resorption. Alterations of the thyroid axis in malnutrition are controversial (24). In our study, T 3 levels were low at
5 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) 146 the beginning of treatment, within the low limits of normality during 1 year of treatment and were normalized after the follow-up period. This could be involved in the loss of bone mass in this group of patients since thyroid hormones exert biological effects on the growth cartilage by stimulating mineralization of the matrix, as well as on the formation and reabsorption of bone (25). Insufficient nutrient intake inhibits the secretion of gonadotropins, preventing or delaying the onset of puberty. In addition to effecting low IGF-I levels, this results in a smaller growth spurt and a lower mineral deposit in the bone mass, as observed in these patients (26). Sex steroids promote skeletal restoration, bone mineralization and the growth spurt. The effects of sex steroids on the acquisition of bone mass can be direct, as well as indirect through modulation of local growth factors, GH, IGF-I and 1 25-OH vitamin D (27). Their influence on the acquisition and maintenance of the bone mass has been widely demonstrated in postmenopausal women. However, in patients with AN they do not seem to stimulate a significant increase in bone mass (28). Other factors, such as low calcium intake and low levels of IGF-I, are most likely implicated and the presence of estrogens is necessary, but not sufficient, for adequate mineralization (29). Recent studies suggest that the administration of other sex steroids, such as dehydroepiandrosterone (DHEA), most likely acting through aromatization to estrogen in peripheral tissues, could be used to treat these patients. Indeed, DHEA stimulates human osteoblast cell proliferation through the androgen receptor and preliminary findings suggest that DHEA has both anabolic and anti-osteolytic properties. Longitudinal studies are needed to determine the long-term biological actions of this agent, including its effects on bone mass (30). As we have previously demonstrated, leptin levels in patients with AN are significantly reduced, as might be expected in light of their dramatically reduced levels of body fat (31). However, there was no significant correlation between BMI SDS and leptin levels in these patients. Surprisingly, leptin levels did not rise significantly after recuperation of at least 10% of the original body mass (31). Even those patients who achieved a BMI within the normal range did not exhibit significant increases in their leptin levels. One possible explanation may be that these patients must maintain a normal body weight for a longer period of time in order to return their leptin levels to normal. Another possibility is that total leptin levels in these patients do not rise significantly with partial weight recovery, but that the proportion of this protein in the free, or presumably biologically active fraction, does increase. These possibilities deserve further investigation. In conclusion, our data demonstrate that despite its usefulness in perimenopausal women, estrogen and gestagen administration does not reverse the profound osteopenia seen in young women with AN. Trabecular bone loss is severe and may progress despite estrogen therapy. Other factors, such weight loss, duration of the amenorrhea and low IGF-I levels, could contribute to the loss of bone mass in women with AN. Future investigation is needed to address the effect of early intervention on preserving bone mass in this increasing population of young women. Acknowledgements The authors would like to thank Dr J. A. Chowen for the critical review of the manuscript. This work was supported by grants from the Comunidad of Madrid and Fundación Endocrinología y Nutrición. References Effects of estrogen on BMD in anorexia nervosa 49 1 Carmichael KA & Carmichael DH. Bone metabolism and osteopenia in eating disorders. Medicine Muñoz MT, Morandé G, García-Centenera JA, Hervás F & Argente J. Implications of calcium phosphate metabolism in the development of osteopenia in adolescents with anorexia nervosa. Hormone Research (Suppl 2) Klibanski A, Biller BM, Schoenfeld DA, Herzog DB & Saxe VC. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism Soyka LA, Grinspoon S, Levitsky LL, Herzog DB & Klibanski A. The effect of anorexia nervosa on bone metabolism in female adolescents. Journal of Clinical Endocrinology and Metabolism Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington DC: American Psychiatry Association, Hernández M, Castellet J, Narvaiza JL, Rincòn JM, Rviz I & Sanchez E. Curvas y tablas de crecimiento. Eds M Hernández & Fundación F Orbegozo. Madrid: Editorial Garsi, Del Río L, Carrascosa A, Pons F, Gusinyé M, Yeste D & Domenech FM. Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: change related to age, sex and puberty. Pediatric Research WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization Technical Report Series Gulekli B, Davies MC & Jacobs HS. Effect of treatment on established osteoporosis in young women with amenorrhea. Clinical Endocrinology Bachrack LK, Guido D, Katzman D, Litt Y & Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics Rigotti NA, Nussbaum SR, Herzog DB & Neer RM. Osteoporosis in women with anorexia nervosa. New England Journal of Medicine Bachrach LK, Katzman DK, Litt IF, Guido D & Marcus R. Recovery from osteopenia in adolescent girls with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism Recker RR, Davies KM & Hinders SM. Bone gain in young adult women. JAMA Golden NH, Jacobson MS, Schebendach J, Solanto MV, Hertz SM & Shenker IR. Resumption of menses in anorexia nervosa. Archives of Pediatric Adolescent Medicine Hergenroeder AC. Bone mineralization, hypothalamic amenorrhea and sex steroid therapy in female adolescents and young adults. Journal of Pediatrics Lichtenbelt M, Heidendal GA & Westerterp KR. Energy expenditure and physical activity in relation to bone mineral density in women with anorexia nervosa. European Journal of Clinical Nutrition
6 50 M T Muñoz and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002) Emans SJ, Grace E & Hoffer FA. Estrogen deficiency in adolescents and young adults impacts on bone mineral content and effects of estrogen replacement therapy. Obstetrics and Gynecology Johnston GC, Miller JZ, Slemenda CHW, Resiter TK, Siu HUI D, Christian JC et al. Calcium supplementation and increase in bone mineral density in children. New England Journal of Medicine Argente J & Pozo J. Factores de crecimiento y nutrición: aspectos pediátricos. Endocrinología (Suppl 2) Seeman E, Szmukler GI & Formica C. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive and exercise. Journal of Bone Mineral Research Muñoz MT & Argente J. Anorexia nerviosa y bulimia nerviosa. In Tratado de Endocrinología Pediátrica y de la Adolescencia, pp Eds J Argente, A Carrascosa, R Gracia & F Rodríguez. Barcelona: DOYMA, Argente J, Caballo N, Barrios V, Muñoz MT, Pozo J, Chowen JA, Morandé G & Hernández M. Multiple endocrine abnormalities in the growth hormone (GH) and insulin-like growth factor (IGF) axes in patients with anorexia nervosa: effect of a short and long-term weight recuperation. Journal of Clinical Endocrinology and Metabolism Grinspoon S, Baum H, Lee K, Anderson E, Herzog D & Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism Croxson MS & Ibbertson HK. Low serum triidothyronine (T 3 ) and hypothyroidism in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism Norris PD, O Malley BP & Palmer RL. The TRH test in bulimia and anorexia nervosa: a controlled study. Journal of Psychiatric Research Grinspoon S, Herzog D & Klibanski A. Mechanisms and treatment options for bone loss in anorexia nervosa. Psychopharmacology Bulletin Guleki B, Davies MC & Jacobs HS. Effect of treatment on established osteoporosis in young women with amenorrhea. Clinical Endocrinology Karlsson MK, Weigall SJ, Duan Y & Seeman E. Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa. Journal of Clinical Endocrinology and Metabolism Castro J, Lázaro L, Pons F, Halperin Y & Toro J. Predictors of bone mineral density reduction in adolescents with anorexia nervosa. Journal American Academy of Adolescent Psychiatry Gordon CM, Grace E, Emans SJ, Goodman E, Crawford MH & Leboff MS. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. Journal of Bone Mineral Research Argente J, Barrios V, Chowen JA, Sinha MK & Considine RV. Leptin plasma levels in healthy Spanish children and adolescents, children with obesity and adolescents with anorexia nervosa and bulimia nervosa. Journal of Pediatrics Received 9 February 2001 Accepted 17 September 2001
Hypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement. Hypothalamic amenorrhea NASPAG ACRM 2015
Hypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement Meredith Loveless, MD Gina Sucato, MD MPH NASPAG ACRM 2015 Hypothalamic amenorrhea Functional hypothalamic amenorrhea Absence
More informationANOREXIA nervosa, nervous loss of appetite, was
0021-972X/97/$03.00/0 Vol. 82, No. 7 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Multiple Endocrine Abnormalities of the Growth Hormone and
More information92 Am J Clin Nutr 2007;86:92 9. Printed in USA American Society for Nutrition
Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses 1 3 Jennifer Dominguez, Linnea Goodman,
More informationLeptin: Amenorrhea, Reproduction, Anorexia. Hazel Leung, Ahrad Nathan, Seja Saddy, Judy Tang
Leptin: Amenorrhea, Reproduction, Anorexia Hazel Leung, Ahrad Nathan, Seja Saddy, Judy Tang Introduction: What is leptin? Adipocyte-derived hormone (WAT) Receptor roles Class I cytokine receptor superfamily
More informationAN INVESTIGATION OF THE ASSOCIATIONS AMONG RECOVERY, KEY ILLNESS CHARACTERISTICS AND BONE MINERAL DENSITY IN WOMEN WITH A HISTORY OF ANOREXIA NERVOSA
AN INVESTIGATION OF THE ASSOCIATIONS AMONG RECOVERY, KEY ILLNESS CHARACTERISTICS AND BONE MINERAL DENSITY IN WOMEN WITH A HISTORY OF ANOREXIA NERVOSA by Esther J. Waugh A thesis submitted in conformity
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationBecause the low bone mass and deterioration
OSTEOPOROSIS A look at recent expert guidelines and key studies in bone health, the findings of which affect your patients young and old Steven R. Goldstein, MD Dr. Goldstein is Professor of Obstetrics
More informationEuropean Journal of Endocrinology (1998) ISSN
European Journal of Endocrinology (1998) 139 276 283 ISSN 0804-4643 The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationToo much of a good thing
Too much of a good thing The Female Athlete Triad: Toward improved screening and management Asma Javed Pediatric and Adolescent Gynecology Mayo Clinic, Rochester Disclosure No relevant financial disclosure
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationLinkoping University/ Sweden An-Najah National University Nursing College College of Higher Educaion. Dr Aidah Abu Elsoud Alkaissi
Dr. Aidah Abu Elsoud Alkaissi Linkoping University/ Sweden An-Najah National University Nursing College College of Higher Educaion 1 Are predominantly diseases of females, who comprise between 90% and
More informationFemale Athlete Triad. Shea Teresi. SUNY Oneonta
1 Female Athlete Triad Shea Teresi SUNY Oneonta 2 Physical activity, along with eating nutritiously, are a very important and essential aspect in maintaining a healthy lifestyle for both men and women.
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationThe effects of anorexia nervosa on bone metabolism in female adolescents
University of Massachusetts Medical School escholarship@umms Endocrinology/Diabetes Pediatric Divisions 12-22-1999 The effects of anorexia nervosa on bone metabolism in female adolescents Leslie A. Soyka
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationAbnormal bone mineral accrual in adolescent girls with anorexia nervosa
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 9-6-2002 Abnormal bone mineral accrual in adolescent girls with anorexia nervosa
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationWEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH
MENOPAUSE WHEN DOES IT OCCUR? The cessation of the menstrual cycle for one year. WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH Jan Schroeder, Ph.D. Chair of The Department of Kinesiology California State
More informationReproductive physiology
Reproductive physiology Sex hormones: Androgens Estrogens Gestagens Learning objectives 86 (also 90) Sex Genetic sex Gonadal sex Phenotypic sex XY - XX chromosomes testes - ovaries external features Tha
More informationENDOCRINOLOGY COORDINATION OF PHYSIOLOGICAL PROCESSES:
ENDOCRINOLOGY COORDINATION OF PHYSIOLOGICAL PROCESSES: -In a living organism there must be coordination of number of physiological activities taking place simultaneously such as: movement, respiration,
More informationEndocrine secretion cells secrete substances into the extracellular fluid
Animal Hormones Concept 30.1 Hormones Are Chemical Messengers Endocrine secretion cells secrete substances into the extracellular fluid Exocrine secretion cells secrete substances into a duct or a body
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationLeptin levels and menstrual function in HIV-infected women in rural India
Leptin levels and menstrual function in HIV-infected women in rural India Annie Phoebe. K¹, Mini Jacob.S¹, Hemalatha.R², Sivakumar M.R¹ ¹Department of Experimental Medicine, The Tamil Nadu Dr. MGR Medical
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCHAPTER 41: Animal Hormones
CHAPTER 41: Animal Hormones 1. List a few similarities and differences comparing: a. endocrine system b. nervous system 2. What is the difference between endocrine and exocrine glands? 3. What is the difference
More informationPEAK BONE MASS can be defined as the maximal bone
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society CLINICAL REVIEW 117 Hormonal Determinants and Disorders
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationExercise Training, Menstrual Irregularities and Bone Development in Children and Adolescents. Introduction
J Pediatr Adolesc Gynecol (2003) 16:201 206 Mini-Review Exercise Training, Menstrual Irregularities and Bone Development in Children and Adolescents Alon Eliakim, MD 1 and Yoram Beyth, MD 2 1 Child Health
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationUniversity of Bristol - Explore Bristol Research
Robinson, L., Aldridge, V., Clark, E. M., Misra, M., & Micali, N. (2017). Pharmacological treatment option for low Bone Mineral Density and secondary osteoporosis in Anorexia Nervosa: A systematic review
More informationDietary Intake and Bone Mineral Density Status Among Adolescents of Kurukshetra
Journal of Food and Nutrition Sciences 2017; 5(3): 63-68 http://www.sciencepublishinggroup.com/j/jfns doi: 10.11648/j.jfns.20170503.11 ISSN: 2330-7285 (Print); ISSN: 2330-7293 (Online) Dietary Intake and
More informationDM and Osteoporosis. Why is it important?
DM and Osteoporosis Why is it important? Diabetes Osteoporosis Fractures Dr Pedro Conthe HGUGM Madrid Spain Agenda: DM and Osteoporosis Observational studies Physiopathology of bone Type I and Type 2 DM
More information2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationGrowth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D.
Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D. I. Growth Hormone (somatotropin): Growth hormone (GH) is a 191 amino acid single chain polypeptide (MW 22,000 daltons). Growth
More informationSomatostatin Analog and Estrogen Treatment in a Tall Girl
Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More informationBone mineralization disorders as a complication of anorexia nervosa etiology, prevalence, course and treatment
Psychiatr. Pol. 2016; 50(3): 509 520 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/59289 Bone mineralization disorders as a complication
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationRelative Energy Deficiency Syndrome. Alexandra Myers, D.O., M.S.H.S., CAQSM October 6, 2018 AOASM
Relative Energy Deficiency Syndrome Alexandra Myers, D.O., M.S.H.S., CAQSM October 6, 2018 AOASM Disclosures None Background Family Medicine/Sports Medicine San Diego State University Director of Women
More informationINTRODUCTION. Original Article
J Bone Metab 2015;22:135-141 http://dx.doi.org/10.11005/jbm.2015.22.3.135 pissn 2287-6375 eissn 2287-7029 Original Article Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients
More informationThe Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors
The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine
More informationRegulation of the skeletal mass through the life span
Regulation of the skeletal mass through the life span Functions of the skeletal system Mechanical protection skull Movement leverage for muscles Mineral metabolism calcium store Erythropoiesis red blood
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationUniversity of Medicine and Pharmacy Craiova. Faculty of Medicine. PhD THESIS ABSTRACT
University of Medicine and Pharmacy Craiova Faculty of Medicine PhD THESIS ABSTRACT STUDY OF THE CHANGES IN BONE MASS AND BONE METABOLISM MARKERS IN THYROTOXIC OSTEOPOROSIS. THERAPEUTIC IMPLICATIONS. Scientific
More informationEffects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More informationPFIZER INC. PROTOCOL TITLE: Metabolic effects of growth hormone (Genotonorm ) in girls with Turner syndrome.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPreface Acknowledgments Introduction Introductory Concepts Definitions and Context Chronological Age and Age Groups Why Study These Phenomena?
Preface Acknowledgments Introduction Introductory Concepts Definitions and Context Chronological Age and Age Groups Why Study These Phenomena? Types of Studies Principles of Measurement and Observation
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationAdaptation and re-feeding Hypokalemia Bone complications
Adaptation and re-feeding Hypokalemia Bone complications René Klinkby Støving Odense University Hospital Denmark 10% 20% 30% 40% BMI 18.5 BMI 16.5 BMI 14.5 BMI 12.5 Willmore DW, The Metabolic Management
More informationPremenopausal osteoporosis, an overlooked consequence of anorexia nervosa
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will recognize the risk of osteoporosis in patients with anorexia nervosa KATHRYN TENG, MD Department of Internal Medicine, and Director, Clinical Integration
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationThe bone mass concept: problems in short stature
European Journal of Endocrinology (2004) 151 S87 S91 ISSN 0804-4643 The bone mass concept: problems in short stature E Schoenau, C Land, A Stabrey, T Remer 1 and A Kroke 1 Children s Hospital, University
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationGONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
original paper Haematologica 1994; 79:141-147 GONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA Fiorina Giona*, Luciana Annino*, Paola Donato, Michele
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationAbstract. Introduction CLINICAL STUDY
European Journal of Endocrinology (2010) 162 905 911 ISSN 0804-4643 CLINICAL STUDY Increased circulating adiponectin levels and decreased leptin/soluble leptin receptor ratio throughout puberty in female
More informationGrowth and DMD Endocrine aspects of care
Growth and DMD Endocrine aspects of care Meilan Rutter, MB,BCh, FRACP Division of Endocrinology Cincinnati Children s Hospital Medical Center July 2007 Where are we now? Inactive Reactive Proactive CCHMC
More informationThe University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Endocrinology
The University of Arizona Pediatric Residency Program Primary Goals for Rotation Endocrinology 1. GOAL: Understand the role of the pediatrician in preventing endocrine dysfunction, and in counseling and
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationHormones. Introduction to Endocrine Disorders. Hormone actions. Modulation of hormone levels. Modulation of hormone levels
Introduction to Endocrine Disorders Hormones Self-regulating system (homeostasis) Affect: Growth Metabolism Reproduction Fluid and electrolyte balance Hormone actions Endocrine gland Hormone synthesis
More informationI. Endocrine System & Hormones Figure 1: Human Endocrine System
I. Endocrine System & Hormones Figure 1: Human Endocrine System Endocrine System: a) Endocrine glands are ductless since they lack specific vessels for the transport of hormones throughout the body. Instead,
More informationLaura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia
Precocious Puberty Laura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia Faculty Disclosure Faculty: Laura Stewart No relationships with
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationReceptors Functions and Signal Transduction L1- L2
Receptors Functions and Signal Transduction L1- L2 Faisal I. Mohammed, MD, PhD University of Jordan 1 Introduction to Physiology (0501110) Spring 2013 Subject Receptors: types and adaptation - Membrane
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationEffects of transdermal estrogen on body composition in adolescent female athletes
Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2013 Effects of transdermal estrogen on body composition in adolescent female athletes Sims,
More informationLab Activity 21. Endocrine System Glucometer. Portland Community College BI 232
Lab Activity 21 Endocrine System Glucometer Portland Community College BI 232 2 Hormone Functions ACTH (adrenocorticotropic hormone) Regulates the activity of the cortex of the adrenal gland TSH (thyroid
More informationOsteoporosis: Who, What, When, Why, and How
Osteoporosis: Who, What, When, Why, and How Doris J. Uh, PharmD, AE-C Pharm 445 September 20, 2005 Objectives define osteoporosis (what) determine high risk groups (who, when) review modifiable, non-modifiable
More informationHormones and the Endocrine System Chapter 45. Intercellular communication. Paracrine and Autocrine Signaling. Signaling by local regulators 11/26/2017
Hormones and the Endocrine System Chapter 45 Intercellular communication Endocrine signaling Local regulators Paracrine and autocrine signaling Neuron signaling Synaptic and neuroendocrine signaling Paracrine
More informationSerum kisspeptin concentrations are negatively correlated with body mass index in adolescents with anorexia nervosa and amenorrhea
HORMONES 2017, 16(1):33-41 Research paper Serum kisspeptin concentrations are negatively correlated with body mass index in adolescents with anorexia nervosa and amenorrhea Flora Bacopoulou, 1 George I.
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More information